Eli Radiopharma Closes Nearly RMB 400 Million Series A

Company Hangzhou Eli Radiopharma Event Type Series A financing (nearly RMB 400 million) Modality Radiopharmaceutical Asset Undisclosed preclinical programs Target Undisclosed Disease Area Oncology; neurological disease Summary Hangzhou Eli Radiopharma disclosed a newly closed Series A of nearly RMB 400 million. The company-origin English release…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *